Navigation Links
PROLOR Biotech To Present New Data On Its Long-Acting Human Growth Hormone And Long-Acting Oxyntomodulin At ENDO 2013
Date:6/13/2013

SAN FRANCISCO and NES-ZIONA, Israel, June 13, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH), today announced that the company will present new data on its long-acting human growth hormone (hGH-CTP) in Phase III development for the treatment of growth hormone deficiency and its long acting oxyntomodulin (MOD-6030) in preclinical development for the treatment of obesity and type 2 diabetes at ENDO 2013, the 95th Annual Meeting of the Endocrine Society.PROLOR's scientists will present additional pre-clinical and clinical safety data on hGH-CTP and will discuss its manufacturing process.  Data previously reported by the company confirmed that hGH-CTP appears to be safe and well tolerated and that it has the potential to be administered once-weekly to adults with growth hormone deficiency.  The new data provides further information on the excellent safety and tolerability profile of hGH-CTP in a variety of pre-clinical and clinical studies.  PROLOR recently announced that it has initiated a pivotal Phase III study of hGH-CTP in growth hormone deficient adults.

In addition, PROLOR scientists will make an oral presentation discussing MOD-6030, also known as LA-Oxyntomodulin, the company's long-acting GLP-1 and Glucagon dual agonist with potential for the treatment of type 2 diabetes and obesity.  New pre-clinical data will be presented on MOD-6030's effects on weight reduction and glucose tolerance in animal models.

The PROLOR presentations include the following:

FP02-3:  The Long-Acting Dual GLP-1/Glucagon Agonist, Mod-6030, Improves Glycemic Control and Induces a Prolonged Weight Loss in Diet-Induced Obesity Mice Following a Once-Weekly Administration.  See abstract for more information.

SAT-120:  Metabolic and Safety Parameters of Once-Weekly, CTP-
'/>"/>

SOURCE PROLOR Biotech, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces Investigation into Possible Breaches of Fiduciary Duty by the Board of PROLOR Biotech, Inc. in Connection with the Sale of the Company to OPKO Health, Inc.
2. Law Office of Brodsky & Smith, LLC Announces Investigation of PROLOR Biotech, Inc.
3. OPKO Health To Acquire PROLOR Biotech
4. PROLOR Biotech To Present New Preclinical Data On Its Long-Acting Clotting Factor VIIa At Leading European Scientific Conference
5. PROLOR Biotech to Present Data on Its Long-Acting Human Growth Hormone at Pediatric Endocrinology Meeting
6. PROLOR Biotech To Present Data On Its Long-Acting Human Growth Hormone At International NeuroEndocrine Meeting
7. PROLOR Biotech Announces Presentation of Data on Its Long-Acting Clotting Factors at World Federation of Hemophilia World Congress
8. Data From Phase II Trial of Prolor Biotechs Long-acting Human Growth Hormone Presented at Endo 2012
9. Zacks Investment Ideas feature highlights: Market Vectors Biotech ETF, iShares Nasdaq Biotechnology ETF, Regeneron, Celgene and First Trust Amex Biotechnology Index Fund
10. MedReps.com Report Shows Biotech Workers Earn the Most in Medical Sales
11. Biotechnology Master’s at UMBC Shady Grove - Virtual Info Session to Be Held on June 26
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... , March 5, 2015  DuPont (NYSE: ... Aviation, Transportation and Industrials Conference held today in ... Matthew L. Trerotola discussed strategy, progress and ... segments for DuPont.  Strengthening and growing the company,s leading ... three areas of strategic priority for DuPont. ...
(Date:3/5/2015)... -- Twelve patients today are preparing to participate in a ... Pacific Medical Center (CPMC), a Sutter Health affiliate. ... the largest single-center kidney paired donation chain conducted on ... 44-year history of the CPMC Transplant Center. The two-day ... donor who did not have a specific recipient in ...
(Date:3/5/2015)... March 5, 2015   HX360 today announced ... the HX360 Innovation Challenge competition. These companies, ... to be chosen as one of four finalists to ... health system executives and venture capitalists during the Innovation ... takes place at the 2015 HIMSS Annual Conference & ...
(Date:3/5/2015)... York (PRWEB) March 05, 2015 LifeCell ... to be able to get an Advanced Semen Analysis ... stress, blaming and guessing are all risk factors for ... the woman is the source of the infertility. Infertility ... LifeCell Dx has the simplest, least complicated and ...
Breaking Biology Technology:DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 2DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 3DuPont Leader Highlights Strategy, Progress and Plans to Accelerate Growth in Advanced Materials and Discusses Near-Term Outlook 4Altruistic donor starts large West Coast single-center kidney paired donation at CPMC 2Altruistic donor starts large West Coast single-center kidney paired donation at CPMC 3Altruistic donor starts large West Coast single-center kidney paired donation at CPMC 4HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 2HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 3HX360 Announces Sixteen Innovation Challenge Semi-finalists Competing To Deliver Solutions That Improve The Patient Experience 4LifeCell Dx Offers New Option to Veterans with Infertility 2LifeCell Dx Offers New Option to Veterans with Infertility 3
... trials show that Emulin(TM), a plant-based extract, is better than metformin, ... in human beings. , ... Winter Haven, FL (PRWEB) ... blood sugar levels in Type 2 diabetics better than a leading ...
... Covers Development of Gene Expression Signatures Derived by ... as Molecular Test of Responsiveness to Current Treatments, ... /PRNewswire-FirstCall/,-- Transgenomic (OTC Bulletin Board: TBIO) today announced ... diagnostic test which will guide,clinicians in their choice ...
... Technology Targets Tumors with Precise Image-Guided IMRT to Spare Healthy ... ... ALTO, Calif., Sept. 16 Doctors at cancer,treatment centers in ... neck cancer using RapidArc(TM) radiotherapy technology from Varian,Medical Systems (NYSE: ...
Cached Biology Technology:Human Trial Results Show Plant Extract Tops Drug at Regulating Blood Sugar Levels; Huge Market Seen for Newly Developed Food Additive Emulin™ 2Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options 2Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options 3Transgenomic Announces Partnership With Key Genomics for Ovarian Cancer Assay to Guide Therapeutic Options 4Doctors in the US and Netherlands Using Fast RapidArc Radiotherapy Technology to Help Fight Cancer are Now Treating Tumors of the Head and Neck 2Doctors in the US and Netherlands Using Fast RapidArc Radiotherapy Technology to Help Fight Cancer are Now Treating Tumors of the Head and Neck 3
(Date:3/5/2015)... , March 5, 2015 In ... percent of companies already using these solutions and 42 percent ... Of the latter, approximately 25 percent of the companies will ... While the majority of companies in the region are ... that the hybrid model will command significant attention in the ...
(Date:3/4/2015)... DUBLIN , Mar. 04, 2015 Research ... announced the addition of the "Global Biometrics ... their offering. The market for biometric ... CAGR of around 14% till 2020 ... will be increasing security needs, government projects and ...
(Date:3/3/2015)... , March 3, 2015 Cryoport, ... of advanced cryogenic logistics solutions for the ... stem cells, cell lines, clinical research organizations, ... today announced the expansion of its relationship ... ("Fred Hutch") Clinical Research Division with ...
Breaking Biology News(10 mins):Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 2Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 3Two of Every Three Brazilian Companies will have Invested in Cloud by 2015, Finds Frost & Sullivan 4Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3
... landmark genetic study has identified multiple genes linked to ... disease that affects an estimated 1.4 million Americans. ... brain and blood and occurs in about 31 out ... likely than men to develop the condition, which is ...
... from the January issue of Mayo Clinic Proceedings include ... workplace drug screening and the safety and effectiveness of ... Examine the Effect of Antioxidant Supplements on Cancer ... cancer and deaths related to cancer? Thats a question ...
... The National Academy of Sciences, Sackler Colloquium series ... These networks represent the genomic program for ... cell types. The meeting will focus on ... early embryonic development; gene networks later developmental processes; ...
Cached Biology News:Steps toward Stopping Autoimmune Disease 2Mayo Clinic Proceedings January tip sheet 2Mayo Clinic Proceedings January tip sheet 3
Direct ELISA Assay Diluent, 100 mL...
Assay Diluent Trial Pack, 4 x 100 mL...
SpectroQuest single beam 1.8nm UV/Vis spectrophotometer; stand-alone unit...
...
Biology Products: